The legislation would end the mandate on animal testing for drug and cosmetic development in
BICO, a leading bio convergence company, announced today it is endorsing the bipartisan FDA Modernization Act of 2021. The bill, H.R. 2565 / S.2952, would allow drug and cosmetic makers to develop new products using non-animal models including cell-based assays, organ chips and micro physiological systems, sophisticated computer modelling, and other human biology-based test methods. Since its founding, BICO has been a leader in the effort to end animal testing in the life sciences community, and plan to actively build support for the legislation.
Each year more than 100 million animals are estimated to be experimented on and euthanized for use in biomedical research in
There is an ongoing global debate concerning the relevance of animal testing. In
"There is no bigger ethical issue plaguing the life sciences industry in
Nearly all BICO's 13 group companies contribute to advancing drug development including several that provide direct alternatives to animal testing, including:
CELLINK - 3D bioprinting to fabricate human tissue samples that provide much more physiologically relevant drug testing than animals.- MatTek - In vitro human tissue models including skin, ocular, oral, respiratory, and intestinal tissue models to replicate toxicity and efficacy of human cells.
- Visikol - In Vitro assays for drug screening and toxicity assessment using high content screening, confocal microscopy, ELISA, and other assays.
- SCIENION - automated precision dispensing that can be used to accurately and reproducible distribute physiologically relevant biological material.
- Cellenion - single large-particle sorting and dispensing technology that enables the handling of complex 3D cellular models such as spheroids and organoids, and that can replace animal testing in pre-clinical research.
"Human tissue replacement models are undoubtably a better indicator of toxicity and efficacy than dogs or mice, which share very little physiology to humans," says
To learn more about BICO's efforts to reduce animal testing, please visit: www.bico.com/reduce-animal-testing
United States House Bill, H.R 2565 - FDA Modernization Act of 2021
Article in the Cambridge Quarterly of Healthcare Ethics "The Flaws and Human Harms of Animal Experimentation"
Riley Munks, PR Manager: + 1 (650) 863-6699
Alyssa D'Orazio, PR Manager: + 1 (617) 634-9601
Email: press@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on
About BICO
Founded in 2016, BICO (formerly
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO's technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
https://news.cision.com/bico-group/r/bico-endorses-fda-modernization-act-of-2021,c3471946
https://mb.cision.com/Main/14960/3471946/1509645.pdf
(c) 2021 Cision. All rights reserved., source